B Cell Lymphoma

EHA/ICML Conference Highlights: Monoclonal Antibodies, Bispecific Antibodies, and ADCs Drive Efficient and Low-Toxicity Treatment Evolution for Lymphoma

by
EHA/ICML Conference Highlights: Monoclonal Antibodies, Bispecific Antibodies, and ADCs Drive Efficient and Low-Toxicity Treatment Evolution for Lymphoma

At the recent 2025 European Hematology Association (EHA) Annual Meeting and the International Conference on Malignant Lymphoma (ICML), not only were continuous breakthroughs in the field of lymphoma treatment witnessed, but a series of studies also validated the immense potential of precision immunotherapy in enhancing patient survival benefits. “Blood News” focuses on this international event, … Read more

Turning Dreams into Reality: Roche’s CD3 Bispecific Antibody Combined ADC Shows Exceptional Efficacy, Expanding the CD3 Bispecific ADC Concept

by
Turning Dreams into Reality: Roche's CD3 Bispecific Antibody Combined ADC Shows Exceptional Efficacy, Expanding the CD3 Bispecific ADC Concept

▎Trace Back Three years ago, when I wrote analyses on the CD3 bispecific antibody combined ADC, it was often considered an overly aggressive therapy. However, Roche has made significant explorations in this area. When the CD3/DLL3 ADC from Wuxi Biologics was released, many in the industry were puzzled, but there is no need for surprise. … Read more